Antibody-Drug Conjugate Linker Simplification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery methods, such as parenteral and oral administration, often result in systemic distribution and non-specific toxicity due to lack of targeted delivery, leading to adverse effects and limited dosing, particularly for cancer treatment where cytotoxic agents are concerned.
Innovation Solution
Development of antibody-drug conjugates with enzymatically cleavable linkers that do not require self-immolative spacers for efficient drug release, allowing targeted delivery and intracellular accumulation of cytotoxic agents to tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibody-drug conjugates use enzymatically cleavable linkers with self-immolative spacers for drug release, then drug release efficiency is improved, but device complexity and manufacturing complexity increase
Solution Approach 1:
The patent extracts and removes the self-immolative spacer component from the linker structure, demonstrating that efficient drug release can be achieved through enzymatic cleavage of the linker itself without requiring additional self-immolative spacer units. This simplifies the overall conjugate structure while maintaining therapeutic efficacy.
Solution Approach 2:
The invention modifies specific local regions of the linker to enable direct enzymatic cleavage and drug release, rather than requiring a multi-component system. The linker is designed with specific amino acid sequences that are directly recognizable and cleavable by target cell enzymes, eliminating the need for separate self-immolative spacer modules.
2Ease of operation
If systemic administration of unconjugated drug agents is used, then ease of administration is improved, but object-affected harmful factors increase due to toxicity to normal cells
Solution Approach 1:
The patent introduces an antibody component as an intermediary that specifically targets tumor cells. The antibody-drug conjugate uses the antibody to recognize and bind to tumor cell surface antigens, delivering the cytotoxic drug selectively to tumor cells while sparing normal cells, thus maintaining ease of systemic administration while reducing off-target toxicity.
Solution Approach 2:
The invention creates a heterogeneity in drug distribution by concentrating the cytotoxic agent specifically at the tumor site through antibody targeting, rather than uniform systemic distribution. This localized delivery mechanism maintains the convenience of systemic administration while minimizing exposure and toxicity to normal tissues.
3Object-affected harmful factors
If targeted delivery using antibody-drug conjugates is implemented, then object-affected harmful factors are reduced, but device complexity increases
Solution Approach 1:
The patent removes unnecessary components from the conventional antibody-drug conjugate structure, specifically eliminating the self-immolative spacer requirement. The simplified linker design maintains targeted delivery capability while reducing structural complexity and potential manufacturing challenges.
Solution Approach 2:
The invention designs a multifunctional linker that simultaneously provides: (1) stable attachment to the antibody, (2) enzymatic cleavability for drug release, and (3) appropriate pharmacokinetic properties. This consolidated design eliminates the need for separate self-immolative spacer units while maintaining all necessary functions for effective targeted delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables targeted delivery of cytotoxic agents to tumor cells, reducing toxicity to normal cells and enhancing the therapeutic index by facilitating controlled release of drugs within cancer cells, thereby improving treatment efficacy while minimizing side effects.
Implementation Method 1
Once internalized, the drug can be released from the antibody by cleavage in the lysozme or by other cellular mechanism. To facilitate drug release, a cleavable site can be included in the linker.
Data Source
AI summary
Auristatin-type peptides are disclosed which are highly cytotoxic, synthetically accessible, and can be conjugated to antibodies and other ligands.